No insider purchase over the last 90 days. The latest, by BlackRockFundAdvisors, was filed 09 Jun 2026.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 85 declarations
HLB Co., Ltd. is a South Korean healthcare company worth KRW 5.74 trillion, of which insiders hold 9.1% of the capital. Its record has 81 filings from 9 filers, with 32 purchases, 2 sales and 47 filings of another kind, so 94% of open-market trades are purchases. Almost none carries an amount: a single purchase is valued, EUR 8,506, filed by 심경재 on April 8, 2024, which rules out any total or median.
심경재, filed as "상무", lodged 24 filings, all purchases. The most frequent filer is 진양곤, under the label "대량보유자", with 37 filings of which 3 are purchases and 1 a sale. The issuer, Hlb, lodged 13, and BlackRockFundAdvisors, also "대량보유자", 2, both purchases. Three filers lodged transactions from February 24, 2026 to March 6, 2026.
Annual volume goes from 23 in 2023 to 6 in 2025. The median publication delay is 4 days. Over the last twelve months: 9 filings, 4 purchases and 2 sales. For 15 purchases, the 90-day median is minus 6.5%, with 27% of results positive, recorded past results and not a forecast.